Sara Kenkare-Mitra, Ph.D., is a distinguished figure in the biopharmaceutical industry, currently serving as the President and Head of Research and Development at ALECTOR INC. With a robust background in drug discovery and development, Dr. Kenkare-Mitra has been instrumental in steering ALECTOR's mission to develop therapies for neurodegenerative diseases. Prior to her role at ALECTOR, she held key positions at several leading biotech companies, including Genentech, where she spearheaded numerous clinical development programs that advanced treatments for cancer and other serious illnesses. Dr. Kenkare-Mitra's career is marked by significant achievements in translating scientific discoveries into viable therapeutic options. Her expertise spans across multiple therapeutic areas, including oncology, immunology, and neurology. At ALECTOR, she oversees a diverse portfolio of programs aimed at modulating the immune system to combat neurodegenerative disorders such as Alzheimer’s and frontotemporal dementia. Her strategic vision and leadership have been pivotal in forging collaborations with academic institutions and industry partners, thereby accelerating the pace of innovation and clinical progress within the company. In her role as President and Head of R&D, Dr. Kenkare-Mitra is responsible for guiding ALECTOR's scientific strategy and ensuring the successful execution of its clinical trials. Her commitment to advancing patient care is evident in her dedication to developing novel therapies that address unmet medical needs. Under her leadership, ALECTOR has made significant strides in its mission to transform the treatment landscape for neurodegenerative diseases, positioning the company as a leader in the field.